PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)65194-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)65194-7/fulltext
Title :
PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65194-7&doi=10.1016/S1098-3015(10)65194-7
First page :
Section Title :
Open access? :
No
Section Order :
353